Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access ...

In the following interview, co-author and panel member Benjamin M. Brucker, MD, provides a detailed walkthrough of these guidelines and discusses their practical implications for clinicians.He ...

Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic ...

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

Panelists discuss how the ZIRCON trial demonstrated high positive predictive value (> 90%) for identifying clear cell renal cell carcinoma using a new molecular imaging agent, though negative ...

Clinical Brief: Bone-Targeted Therapies in Advanced Prostate Cancer. Main Discussion Topics. Therapeutic Goals: Prevention of skeletal-related events and protection of bone health during androgen ...

In this episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with Diane K. Newman, DNP, a nationally recognized expert in pelvic health, to explore the often-overlooked yet vitally ...

A large, retrospective study of nearly 200,000 patients with prostate cancer from the Epic Cosmos database revealed a rise in the use of GLP-1 and GIP/GLP-1 receptor agonists over the past decade, ...

"At the end of the day, it's going to be unlikely that we're going to use a single therapy for all of our patients," says Vignesh T. Packiam, MD. There has been an explosion of treatment options in ...

Panelists discuss the evolving definition of BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), emphasizing its critical role in identifying patients who fail adequate BCG therapy, guiding ...

Panelists discuss how new molecular imaging technology offers potential to better risk stratify patients eligible for adjuvant pembrolizumab after surgery, potentially identifying those who have ...

In the phase 2 COMRADE trial (NCT03317392), reduced-dose olaparib (Lynparza) combined with radium-223 (Ra-223, Xofigo) significantly improved radiographic progression-free survival (rPFS) over Ra-223 ...